See the section "What are the main differences between the EU's Conditional Marketing Authorisation and the Emergency Use Authorisation issued by some other cou

See the section "What are the main differences between the EU's Conditional Marketing Authorisation and the Emergency Use Authorisation issued by some other countries?", onwards. https://ec.europa.eu/commission/presscorner/detail/en/qanda_20_2390 https://ec.europa.eu/commission/presscorner/detail/en/qanda_... (this is from the EC, not as I remembered the EMA) It explains amongst other things that a Conditional Marketing Authorisation (CMA) is a real, controlled and robust, authorisation of the vaccine; this is unlike the Emergency Use Authorisation (EUA), which is really an authorisation of the use of an unauthorised vaccine. A CMA requires data on safety and efficacy, showing the benefits outweigh the risks. An EUA has no such requirement.